Literature DB >> 8791917

MR of recurrent high-grade astrocytomas after intralesional immunotherapy.

M M Smith1, J E Thompson, M Castillo, S Cush, S K Mukherji, C H Miller, K B Quattrocchi.   

Abstract

PURPOSE: To describe the MR findings in six patients with recurrent cerebral astrocytomas before, immediately after, and 3 months after local immunotherapy with tumor-infiltrating lymphocytes and interleukin-2.
METHODS: Contrast-enhanced MR studies were obtained in six patients (three with anaplastic astrocytoma and three with glioblastoma multiforme) at the time of tumor recurrence, after a second resection and placement of an Ommaya catheter, at the end of immunotherapy, and thereafter at 3-month intervals. These MR studies were reviewed with special attention to pattern and degree of enhancement, edema, and mass effect.
RESULTS: In three patients, gross total removal of recurrent tumor was achieved and postimmunotherapy MR studies showed a flare phenomenon characterized by increased nodular enhancement, increased edema, and mass effect. On the 3-month follow-up examination, these findings had resolved, and no further tumor recurrence was seen during the following 12-month period. Neither of the two patients who had subtotal resection had a flare phenomenon. In one of these patients, the tumor was stable at the 12-month follow-up; the other patient had recurrent tumor at the 6-month follow-up. In the last patient, who also had subtotal tumor resection and progressive enhancement after immunotherapy, tumor progression was rapid.
CONCLUSION: After local immunotherapy, increased enhancement, edema, and mass effect are most likely the result of a flare phenomenon, but because rapid tumor progression may produce similar features, follow-up MR studies are indispensable. The flare phenomenon resolved by 3 months in all patients.

Entities:  

Mesh:

Year:  1996        PMID: 8791917      PMCID: PMC8338604     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  13 in total

1.  Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial.

Authors:  Michael D Prados; Michael McDermott; Susan M Chang; Charles B Wilson; James Fick; Kenneth W Culver; John Van Gilder; G Evren Keles; Alex Spence; Mitchel Berger
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.130

2.  Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas.

Authors:  K B Quattrocchi; C H Miller; S Cush; S A Bernard; S T Dull; M Smith; S Gudeman; M A Varia
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

3.  MR imaging and single-photon emission CT findings after gene therapy for human glioblastoma.

Authors:  F W Floeth; A Aulich; K J Langen; K J Burger; W J Bock; F Weber
Journal:  AJNR Am J Neuroradiol       Date:  2001-09       Impact factor: 3.825

4.  Serial CT and MR imaging of carmustine wafers.

Authors:  J M Prager; Y Grenier; J W Cozzens; P Chiowanich; M T Gorey; J R Meyer
Journal:  AJNR Am J Neuroradiol       Date:  2000-01       Impact factor: 3.825

Review 5.  Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patients.

Authors:  John H Rossmeisl; Paulo A Garcia; Gregory B Daniel; John Daniel Bourland; Waldemar Debinski; Nikolaos Dervisis; Shawna Klahn
Journal:  Vet Radiol Ultrasound       Date:  2013-11-13       Impact factor: 1.363

6.  End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria.

Authors:  Martin J van den Bent; Michael A Vogelbaum; Patrick Y Wen; David R Macdonald; Susan M Chang
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

7.  Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin.

Authors:  S Cha; E A Knopp; G Johnson; A Litt; J Glass; M L Gruber; S Lu; D Zagzag
Journal:  AJNR Am J Neuroradiol       Date:  2000-05       Impact factor: 4.966

8.  Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.

Authors:  Aurélie Poli; Jian Wang; Olivia Domingues; Jesús Planagumà; Tao Yan; Cecilie Brekke Rygh; Kai Ove Skaftnesmo; Frits Thorsen; Emmet McCormack; François Hentges; Paal Henning Pedersen; Jacques Zimmer; Per Øyvind Enger; Martha Chekenya
Journal:  Oncotarget       Date:  2013-09

9.  Dynamic contrast enhanced MRI detects early response to adoptive NK cellular immunotherapy targeting the NG2 proteoglycan in a rat model of glioblastoma.

Authors:  Cecilie Brekke Rygh; Jian Wang; Marte Thuen; Andrea Gras Navarro; Else Marie Huuse; Frits Thorsen; Aurelie Poli; Jacques Zimmer; Olav Haraldseth; Stein Atle Lie; Per Øyvind Enger; Martha Chekenya
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

Review 10.  Imaging in gene therapy of patients with glioma.

Authors:  A H Jacobs; J Voges; L W Kracht; C Dittmar; A Winkeler; A Thomas; K Wienhard; K Herholz; W D Heiss
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.